Amylyx in Exclusive AMX0035 Distribution Agreement with Israel-Based Neopharm

 Neopharm gains exclusive rights to commercialize AMX0035 in Israel, Gaza, West Bank, and the Palestinian Authority

- Agreement marks Amylyx’ first distribution partnership since AMX0035 regulatory approvals and commercial launches in the U.S. and Canada

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ("Amylyx" or the "Company") today announced it has entered into an exclusive license and distribution agreement with Neopharm in which Neopharm will commercialize, subject to regulatory review and approval, AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS) in Israel, Gaza, West Bank, and the Palestinian Authority.

https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-exclusive-amx0035-070000794.html